<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00500552</url>
  </required_header>
  <id_info>
    <org_study_id>RRK 2848, 05/Q2707/325</org_study_id>
    <secondary_id>PG/05/087</secondary_id>
    <nct_id>NCT00500552</nct_id>
  </id_info>
  <brief_title>Perhexiline Therapy in Patients With Hypertrophic Cardiomyopathy</brief_title>
  <acronym>METAL-HCM</acronym>
  <official_title>Metabolic Alteration With Perhexiline Therapy in Patients With Hypertrophic Cardiomyopathy (METAL-HCM Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>British Heart Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University College London Hospitals</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypertrophic Cardiomyopathy (HCM) is a relatively common inherited heart muscle disease. Many&#xD;
      patients experience symptoms of breathlessness, fatigue and chest pain. These symptoms are&#xD;
      not always controlled with current therapies.&#xD;
&#xD;
      Recently the investigators showed that a drug called Perhexiline markedly improved exercise&#xD;
      capacity and symptoms in patients with heart failure. In this proposal the investigators wish&#xD;
      to test whether Perhexiline improves exercise capacity and relieves symptoms in patients with&#xD;
      HCM&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:&#xD;
&#xD;
      Hypertrophic cardiomyopathy (HCM) is a complex and relatively common genetic cardiac disease&#xD;
      and it is the most common cause of sudden cardiac death in young people, including trained&#xD;
      athletes. In a recent study using in vivo cardiac MR spectroscopy resting PCr/ATP ratio was&#xD;
      diminished in patients with sarcomeric HCM, indicating reduced energy availability.&#xD;
      Importantly patients with genotypic HCM who did not yet have hypertrophy had a similar degree&#xD;
      of impairment of cardiac PCr/ATP ratio as do patients with marked hypertrophy, implying that&#xD;
      the disturbance may be an early feature of the disease and is not simply due to the&#xD;
      hypertrophy. In medically refractory patients with obstruction, surgical myectomy or alcohol&#xD;
      septal ablation may be very effective. However in patients with non obstructive HCM with&#xD;
      symptoms refractory to standard drug therapy, there are no therapeutic options (apart from&#xD;
      cardiac transplant in very severe cases). Recently, our group showed that Perhexiline, an&#xD;
      antianginal agent with an oxygen-sparing metabolic effect which increases the efficiency of&#xD;
      energy production by shifting substrate utilisation from free fatty acids towards glucose,&#xD;
      was highly effective in improving symptoms, exercise capacity (Vo2max) and cardiac function&#xD;
      in patients with systolic heart failure of both ischaemic and non ischaemic aetiology.&#xD;
&#xD;
      Hypothesis:&#xD;
&#xD;
      The investigators postulate that Perhexiline will improve symptomatic status, peak oxygen&#xD;
      consumption, resting and exercise diastolic function and that this will be associated with&#xD;
      improvement in myocardial energetic status in highly symptomatic medically refractory&#xD;
      patients with non obstructive HCM.&#xD;
&#xD;
      Methods and design:&#xD;
&#xD;
      The study is a multi-centre randomised double blind placebo controlled trial. 50 patients who&#xD;
      meet the entry criteria and provide written informed consent will be recruited to the study.&#xD;
      Patients will be recruited from cardiomyopathy clinics in London, Birmingham and Oxford.&#xD;
&#xD;
      The primary end point will be peak oxygen consumption (Vo2max). Secondary end points will be&#xD;
      resting myocardial energetics (31P Cardiac MR Spectroscopy), resting and exercise diastolic&#xD;
      function (Myocardial Nuclear studies), Symptomatic Status (Minnesota questionnaire)and LV&#xD;
      function (Speckle Tracking Echo measurements).&#xD;
&#xD;
      After the investigations have been performed, subjects will be randomised to receive either&#xD;
      100 mg of Perhexiline a day or placebo for 3 months. Following completions of three months&#xD;
      therapy, these investigations will be repeated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak oxygen consumption (Vo2max)</measure>
    <time_frame>3-4 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>LV function (TDI and 2DS Echo)</measure>
    <time_frame>3-4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic Status (questionnaire)</measure>
    <time_frame>3-4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resting myocardial energetics (31P Cardiac MR Spectroscopy)</measure>
    <time_frame>3-4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic function at rest and during exercise (Nuclear studies)</measure>
    <time_frame>3-4 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Hypertrophic Cardiomyopathy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Perhexiline/Placebo</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Symptomatic Hypertrophic Cardiomyopathy patients&#xD;
&#xD;
          2. Abnormal Peak VO2&#xD;
&#xD;
          3. No significant LVOT obstruction at rest (gradient &lt; 30mmHg)&#xD;
&#xD;
          4. Sinus rhythm&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Abnormal LFT.&#xD;
&#xD;
          2. Concomitant use of amiodarone&#xD;
&#xD;
          3. Pre-existing evidence of peripheral neuropathy.&#xD;
&#xD;
          4. Women of childbearing potential.&#xD;
&#xD;
          5. Patients with ICD's will be excluded from the MR part of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Frenneaux, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>West Midlands</state>
        <zip>B15 2TT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>heart Hospital, University College of London NHS</name>
      <address>
        <city>London</city>
        <zip>W1G 8PH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oxford</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <study_first_submitted>July 10, 2007</study_first_submitted>
  <study_first_submitted_qc>July 10, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2007</study_first_posted>
  <last_update_submitted>November 3, 2010</last_update_submitted>
  <last_update_submitted_qc>November 3, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 4, 2010</last_update_posted>
  <keyword>Perhexiline</keyword>
  <keyword>Hypertrophic Cardiomyopathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Cardiomyopathy, Hypertrophic</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Perhexiline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

